ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "glucocorticoids"

  • Abstract Number: 0297 • ACR Convergence 2020

    Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon

    Melissa Northcott1, Linden Gearing2, Hieu Nim3, Champa Nataraja3, Sarah Jones1 and Eric Morand4, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 2Hudson Institute of Medical Research, Clayton, Victoria, Australia, 3Monash University, Clayton, Victoria, Australia, 4Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: Glucocorticoids (GC), utilised in SLE for their broad immunosuppressive actions, predominantly mediate these effects by interaction with the cytoplasmic GC receptor (GR) to modulate…
  • Abstract Number: 1918 • ACR Convergence 2020

    Efficacy and Safety of Methotrexate in Giant Cell Arteritis: Results from a Bicentric Portuguese Cohort Study

    Sofia Barreira1, Ana Rita Cruz-Machado2, Eduardo Dourado3, Joana Martinho2, Diana Raimundo4, Luísa Brites5, Helena Assunção5, Vítor Teixeira6, Nikita Khmelinskii2, Carla Macieira2, José A. P. da Silva7, João Eurico Fonseca8 and Cristina Ponte2, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, 2Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 3Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, 4Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, 5Rheumatology Department, Centro Hospitalar Universitário Coimbra, Coimbra, Portugal, 6Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 79.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 8Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal

    Background/Purpose: Giant Cell Arteritis (GCA) is a large- and medium-sized vessel vasculitis affecting patients >50 years-old. High-doses of glucocorticoids (GCs) should be initiated promptly to…
  • Abstract Number: 0304 • ACR Convergence 2020

    Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids

    Wendy Dankers1, Melissa Northcott2, Taylah Bennett3, Brendan Russ3, Jacqueline Flynn1, Sarah Jones2 and Eric Morand1, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 3Department of Microbiology, Monash University, Melbourne, Australia

    Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
  • Abstract Number: 1920 • ACR Convergence 2020

    Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment

    Andrea Rubbert Roth1, Scott Tschuppert2, Thomas Neumann2, Ulf Benecke3, Ian Pirker3 and Johannes von Kempis3, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Kantonsspital St Gallen, St.Gallen, Switzerland, 3Kantonspital St Gallen, St. Gallen, Switzerland

    Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…
  • Abstract Number: 0518 • ACR Convergence 2020

    The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis

    Philipp Bosch1, Christian Dejaco2, Wolfgang Schmidt3, Andreas Krause3, Kenny-Davis Schlüter3, Gudrun Pregartner4 and Valentin Schaefer5, 1Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 2Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria and Rheumatology Service, Hospital of Bruneck, Bruneck, Italy, Bruneck, Italy, 3Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, 4Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, Graz, Austria, 5Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

    Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…
  • Abstract Number: 1927 • ACR Convergence 2020

    Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA

    Alwin Sebastian1, Abdul Kayani1, Sue Innes2, Jo Jackson2, Kornelis S. M. van der Geest3 and Bhaskar Dasgupta1, 1Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, 2School of Sport, Rehabilitation and Exercise science, Colchester Campus, University of Essex, United Kingdom, Colchester, England, United Kingdom, 3Rheumatology and Clinical Immunology, University Medical Center Groningen, Netherlands, Groningen, Netherlands

    Background/Purpose: EULAR recommendations highlights ultrasound (US) as the first line imaging investigation for giant cell arteritis (GCA). Traditionally, the halo sign and compression sign have…
  • Abstract Number: 0850 • ACR Convergence 2020

    What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials

    Richard Furie1, Eric Morand2, Ian Bruce3, David Isenberg4, Ronald van Vollenhoven5, Gabriel Abreu6, Lilia Pineda7 and Raj Tummala7, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4Centre for Rheumatology, University College London and Department of Rheumatology, University College Hospital, London, United Kingdom, 5Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg

    Background/Purpose: BICLA is a validated composite global measure of SLE disease activity that incorporates BILAG, an instrument that distinguishes between partial and complete improvement. BICLA…
  • Abstract Number: 1931 • ACR Convergence 2020

    Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis

    Naomi Serling-Boyd1, Xiaoqing Fu2, Yuqing Zhang3, Sebastian Unizony1, Zachary Wallace4, Hyon Choi5 and John H. Stone6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
  • Abstract Number: 0852 • ACR Convergence 2020

    How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis

    Konstantinos Tselios1, Dafna Gladman2, Haifa Al-Sheikh3, Jiandong Su4 and Murray Urowitz1, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3King Faisal Specialist Hospital and Research Centre, Riyadh, Ar Riyad, Saudi Arabia, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

    Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However,…
  • Abstract Number: 1940 • ACR Convergence 2020

    In Newly Diagnosed Giant Cell Arteritis in a Real Life Setting Relapses Are Seen in More Than a Third of Patients – and Despite Faster Early Reduction High Cumulative Glucocorticoid Doses Are Reached

    Laura Felten1, Nicolai Leuchten1 and Martin Aringer2, 1University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany

    Background/Purpose: To investigate real life glucocorticoid (GC) dosing and relapse rates in patients with new onset giant cell arteritis (GCA) in a single center.Methods: Complete…
  • Abstract Number: 0853 • ACR Convergence 2020

    Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz1, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) patients are usually treated with glucocorticoids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid…
  • Abstract Number: 1958 • ACR Convergence 2020

    Patterns and Impact of Long-term Glucocorticoid Use on RA Patients at Risk for Major Adverse Cardiac Events

    Beth Wallace1, Yuqing Gao2, Punyasha Roul3, Bryant England3, Ted Mikuls3, Shirley Cohen-Mekelburg4, Daniel Clauw5, Rodney Hayward1 and Akbar Waljee1, 1Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, 2VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, 3University of Nebraska Medical Center, Omaha, NE, 4Michigan Medicine/VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, 5Michigan Medicine, Ann Arbor, MI

    Background/Purpose: One-quarter to one-third of RA patients use long-term glucocorticoids (GCs) despite their known, dose-dependent association with increased risk of major adverse cardiovascular (CV) events…
  • Abstract Number: 0005 • ACR Convergence 2020

    Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists

    Bella Mehta1, Deanna Jannat-Khah2, Carol Mancuso3, Anne Bass1, Carine Moezinia4, Allan Gibofsky3, Susan Goodman5 and Said Ibrahim6, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York City, NY, 3Hospital for Special Surgery, New York City, 4Hospital for Special Surgery, New York, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Weill Cornell Medicine, Cleveland, OH

    Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
  • Abstract Number: 1083 • ACR Convergence 2020

    Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment

    Sabina Oreska1, Hana Storkanova2, Maja Spiritovic3, Barbora Hermankova4, Michal Vrablik5, Karel Pavelka6, Ladislav Šenolt6, Heřman Mann2, Jiří Vencovský6 and Michal Tomcik7, 1Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, 53rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have…
  • Abstract Number: 1998 • ACR Convergence 2020

    Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis

    Camille Roubille1, Amandine Coffy2, Nathalie Rincheval2, Jean Pierre Daures2, René-Marc Flipo3, Maxime Dougados4 and Bernard Combe5, 1CHU LAPEYRONIE, Montpellier, France, 2INSERM, Montpellier, France, 3Univ-Lille, CHU Lille, department of rheumatology, Lille, France, 4Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, 5University of Montpellier, Montpellier, France

    Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.